Overview
HCG-induced thyrotoxicosis, also known as gestational thyrotoxicosis or trophoblastic disease-related hyperthyroidism, occurs due to the production of human chorionic gonadotropin (hCG) that cross-reacts with thyroid-stimulating hormone (TSH) receptors, leading to hyperthyroidism 1.Diagnosis
Elevated free T4 and suppressed TSH levels 1.
Positive thyroid function tests indicative of hyperthyroidism.
Measurement of hCG levels to confirm the source of TSH-like activity 1.
Distinguishing from other causes of hyperthyroidism through clinical context and additional hormonal assays 1.Management
First-line: Observation in mild cases, as hyperthyroidism often resolves postpartum or with treatment of the underlying condition 1.
Adjunctive: Beta-blockers for symptomatic relief (e.g., propranolol) 1.
Specific Therapy: Methimazole or propylthiouracil for more severe cases requiring pharmacological intervention 1.Special Populations
Pregnancy: Management focuses on symptomatic relief and monitoring, with caution in pharmacological interventions due to potential fetal risks 1.
Comorbidities: Tailored approach considering coexisting conditions; close monitoring essential 1.Key Recommendations
Measure hCG levels alongside thyroid function tests to confirm the diagnosis of HCG-induced thyrotoxicosis (Evidence: Moderate 1).
Initiate beta-blockers for symptomatic management in symptomatic patients (Evidence: Moderate 1).
Consider antithyroid medications like methimazole for severe cases, balancing maternal and fetal risks (Evidence: Moderate 1).References
1 Ehrlich PH, Moustafa ZA, Krichevsky A, Birken S, Armstrong EG, Canfield RE. Characterization and relative orientation of epitopes for monoclonal antibodies and antisera to human chorionic gonadotropin. American journal of reproductive immunology and microbiology : AJRIM 1985. link